CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 6 No. 6
 

Interferon-alfa 2b Activates STAT Proteins in Melanoma Cells

June 1, 1997

CHICAGO--Although interferon-alfa 2b (Intron A) has been used for some time to treat malignant melanoma patients at high risk for relapse after surgery, little has been known about the way in which it works.

A study from Roswell Park Cancer Institute suggests a possible mechanism. The research, reported at the Society for Surgical Oncology cancer symposium, shows that interferon-alfa 2b activates STAT (signal transducer and activator of transcription) proteins in malignant melanoma cell lines and tumor specimens.

Using a gel electrophoresis assay, the researchers found that STAT activation was rapid in melanoma cell lines treated with interferon-alfa 2b, occurring within 30 seconds of administration of a radiolabeled DNA probe, said Roswell Park surgeon William Carson, MD.

Pretreatment with genistein, a tyrosine kinase inhibitor, completely blocked interferon's DNA-binding activity, he added, showing that tyrosine kinase activity is needed for signaling to occur.

Previously frozen melanoma specimens responded to interferon-alfa 2b with a gel shift on electrophoresis, signaling activation of STAT proteins. Fresh specimens also responded to interferon by generating DNA-binding activity.

Interferon-alfa 2b concentrations as low as 102 U/mL activated STAT 1 and STAT 2 proteins. A signaling maximum was achieved with a concentration of 105 U/mL, revealing a distinct dose- response curve for activation of these specific STAT proteins.

Pretreatment with interferon-gamma for 18 hours decreased by more than 1,000-fold the amount of interferon-alfa 2b needed to activate STAT proteins. The researchers believe interferon-gamma is able to enhance the subsequent response to interferon-alfa 2b by acting on the STAT chaperon molecule.

"Interferon-gamma pretreatment has been used with other cytokines without much rationale," he said. "The way it is probably working in this system is by up-regulating levels of the protein chaperon molecule that carries STAT proteins into the nucleus. There is a gene transcription response to interferon-gamma, and protein levels come up within a few hours."

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy